Alan Talevi Pages 3164 - 3170 ( 7 )
Background: In contrast to the one target-one drug paradigm, multi-target agents seem as a promising alternative to manage complex disorders and health conditions linked to drug resistance issues. In fact, many longstanding drugs are in fact unintended multi-functional therapeutics that have emerged from phenotypic screening. The last two decades, however, have witnessed the emergence of tailored multi-target agents, which according to our perspective combine the best aspects of target-based and phenotypic-based drug discovery. Methods: We discuss a number of considerations related to the design, screening and computer-aided discovery of multi-targeted drugs, along with overlooked advantages that this type of agents might have in clinical trials. A theoretic example is included to explain the reduced positive predictive value in virtual screening campaigns focused on multi-target agents. Conclusion: Multi-target agents present great therapeutic potential for the treatment of complex health conditions and the solution of drug resistance phenomena. However, they are certainly challenging for computer-aided drug discovery approaches. Merged or overlapping pharmacophores should be preferred whenever possible. It is thus suggested to perform a careful selection of the combination of pursued targets, preferring target combinations supported by co-evolution or similar biding sites.
Tailored multi-target agents, virtual screening, drug design, in silico screening, binding efficiency metrics, drug resistance, network pharmacology.
Department of Biological Sciences, Faculty of Exact Sciences, La Plata National University (UNLP), B1900AJI, La Plata, Argentina.